# Enveda

> Enveda is a clinical-stage biotech that uses artificial intelligence to read the chemistry of the natural world and turn it into new medicines. Founded in 2019 by Viswa Colluru, the company built PRISM, a foundation model trained on more than a billion mass spectra, to decode the structure of natural molecules that traditional methods leave invisible. That platform has produced a pipeline of small-molecule drug candidates - led by ENV-294, an oral anti-inflammatory now in Phase 2 trials for atopic dermatitis and asthma. Backed by more than $700M in funding and valued as a unicorn, Enveda operates out of Boulder, Colorado and Hyderabad, India.

- **Founded:** 2019
- **Headquarters:** Boulder, Colorado, United States
- **Founders:** Viswa Colluru (Founder & CEO), Pieter Dorrestein (Co-founder / Scientific Founder)
- **Team size:** ~270 employees
- **Products:** Enveda drug discovery platform, PRISM (Pretrained Representations Informed by Spectral Masking), ENV-294, Preclinical pipeline
- **Notable:** Reached unicorn ($1B+) valuation with its September 2025 Series D, Raised more than $700M in total funding across its history, Advanced lead candidate ENV-294 into Phase 2 trials for atopic dermatitis and asthma

## Products & services

- **Enveda drug discovery platform** — An AI-driven platform that reads and translates natural chemistry to identify therapeutic molecules, claimed to discover drugs roughly 4x faster than the industry average by giving access to previously inaccessible natural chemical space.
- **PRISM (Pretrained Representations Informed by Spectral Masking)** — A foundation model trained on over a billion unlabeled mass spectra that interprets mass spectrometry data to elucidate the structures of natural molecules. Developed in collaboration with Microsoft.
- **ENV-294** — Lead candidate - a first-in-class oral anti-inflammatory small molecule derived from natural chemistry. In Phase 2 trials for atopic dermatitis and asthma; Phase 1b showed ~85% mean EASI reduction at Day 42.
- **Preclinical pipeline** — A portfolio of natural-chemistry-derived candidates spanning inflammatory bowel disease (NLRP3/TL1A pathway), fibrotic conditions, and an obesity 'hormone mimetic', plus roughly a dozen earlier-stage programs.

## Achievements

- Reached unicorn ($1B+) valuation with its September 2025 Series D
- Raised more than $700M in total funding across its history
- Advanced lead candidate ENV-294 into Phase 2 trials for atopic dermatitis and asthma
- Reported ~85% mean EASI skin-clearance at Day 42 in a Phase 1b atopic dermatitis trial
- Built PRISM, a foundation model trained on 1B+ mass spectra, in collaboration with Microsoft
- Grew from $55K of founder savings (2019) to a multi-asset clinical-stage company in roughly six years
- Added former Pfizer Chief Scientific Officer Mikael Dolsten to its board

## Latest updates

- **2026-03** — Reported positive Phase 1b results for ENV-294 in moderate-to-severe atopic dermatitis, with ~85% mean EASI reduction at Day 42.
- **2025-12** — Initiated Phase 2 clinical trials of ENV-294, a first-in-class oral therapy, in atopic dermatitis and asthma.
- **2025-09** — Raised $150M Series D led by Premji Invest, reached unicorn status, enrolled first patient in lead program, and added Mikael Dolsten to the board.
- **2024-11** — Raised $130M Series C to advance a pipeline of development candidates toward multiple clinical readouts.
- **2024** — Unveiled PRISM foundation model in collaboration with Microsoft.

## Links

- Website: https://enveda.com
- LinkedIn: https://www.linkedin.com/company/enveda/
- Twitter/X: https://twitter.com/envedabio
- Facebook: https://facebook.com/Enveda-Biosciences-100774851919993/

---

Profile page: https://yespress.io/enveda
Published by YesPress — https://yespress.io
Last updated: 2026-07-12